- Home
- CISS vs OGEN Comparison
CISS vs OGEN Comparison
Compare CISS & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- OGEN
- Stock Information
- Founded
- CISS 2022
- OGEN 1996
- Country
- CISS Greece
- OGEN United States
- Employees
- CISS N/A
- OGEN N/A
- Industry
- CISS Marine Transportation
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- OGEN Health Care
- Exchange
- CISS Nasdaq
- OGEN Nasdaq
- Market Cap
- CISS 2.8M
- OGEN 2.5M
- IPO Year
- CISS N/A
- OGEN N/A
- Fundamental
- Price
- CISS $3.35
- OGEN $1.39
- Analyst Decision
- CISS
- OGEN
- Analyst Count
- CISS 0
- OGEN 0
- Target Price
- CISS N/A
- OGEN N/A
- AVG Volume (30 Days)
- CISS 124.0K
- OGEN 1.2M
- Earning Date
- CISS 08-21-2025
- OGEN 08-08-2025
- Dividend Yield
- CISS N/A
- OGEN N/A
- EPS Growth
- CISS N/A
- OGEN N/A
- EPS
- CISS N/A
- OGEN N/A
- Revenue
- CISS $38,174,754.00
- OGEN N/A
- Revenue This Year
- CISS N/A
- OGEN N/A
- Revenue Next Year
- CISS N/A
- OGEN N/A
- P/E Ratio
- CISS N/A
- OGEN N/A
- Revenue Growth
- CISS N/A
- OGEN N/A
- 52 Week Low
- CISS $2.85
- OGEN $1.34
- 52 Week High
- CISS $23.25
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- CISS 44.02
- OGEN 26.99
- Support Level
- CISS $3.26
- OGEN $1.40
- Resistance Level
- CISS $3.49
- OGEN $1.58
- Average True Range (ATR)
- CISS 0.23
- OGEN 0.28
- MACD
- CISS -0.00
- OGEN -0.13
- Stochastic Oscillator
- CISS 28.72
- OGEN 2.44
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.